2025年8月26日，瑞普生物(300119.SZ)发布2025年中报。 公司营业总收入为17.08亿元，在已披露的同业公司中排名第1，较去年同报告期营业总收入增加2.91亿元，实现3年连续上涨，同比较去年同期上涨 20.53%。归母净利润为2.57亿元，在已披露的同业公司中排名第1，较去年同报告期归母净利润增加9374.42万元，同比较去年同期上涨57.59%。经营活动现 金净流入为1.35亿元，在已披露的同业公司中排名第2。 公司最新总资产周转率为0.21次，在已披露的同业公司中排名第4，较去年同期总资产周转率增加0.06次，同比较去年同期上涨38.57%。最新存货周转率为 1.92次，在已披露的同业公司中排名第4，较去年同期存货周转率增加0.65次，实现2年连续上涨，同比较去年同期上涨50.89%。 公司股东户数为2.62万户，前十大股东持股数量为2.40亿股，占总股本比例为51.75%，前十大股东持股情况如下： | 序号 | 股东名称 | 持股 | | --- | --- | --- | | l | 李守军 | 36.0 | | 2 | 梁武 | 5.10 | | 3 | 鲍恩东 | 2.40 | | ...

Group 1: Financial Performance - The company achieved a revenue of 1.708 billion CNY, a year-on-year increase of 20.53% [3] - Net profit attributable to the parent company reached 257 million CNY, reflecting a growth of 57.59% [3] - The net profit excluding non-recurring gains and losses was 188 million CNY, up 34.28% year-on-year [3] Group 2: Business Segments - The animal health business focused on major clients, significantly boosting revenue from biological products, which became a key growth driver [3] - The pet health segment generated 415 million CNY, a year-on-year increase of 17.94% [5] - The poultry segment saw a revenue of 611 million CNY, growing by 24.71% [9] Group 3: Research and Development - R&D investment reached 114 million CNY, accounting for 6.67% of revenue [3] - The company obtained 4 new veterinary drug registration certificates and 6 clinical trial approvals, including the world's first mRNA vaccine for food animals [3][8] - The R&D achievements contributed to the company's position in the global animal health industry [8] Group 4: Operational Efficiency - The company improved its gross margin by 2.36 percentage points, driven by revenue expansion and product structure optimization [4] - Lean transformation initiatives led to a reduction in sales and management expense ratio by 0.84 percentage points [4] - The raw material drug segment improved its gross margin by 14 percentage points, significantly reducing losses [6] Group 5: Strategic Initiatives - The company is enhancing its supply chain and product matrix in the pet health sector, with plans to launch new products such as cat interferon and probiotics [5] - Strategic partnerships with leading breeding groups are being developed to deepen service and cooperation [4] - The company is focusing on international market expansion and optimizing product structure to increase profitability [6]

Core Insights - Reap Bio (300119.SZ) released its semi-annual report for 2025, indicating that as of August 25, 2025, 10 institutional investors held a total of 24.3797 million A-shares, representing 5.25% of the company's total equity [1] - The top ten institutional investors include notable entities such as Hong Kong Central Clearing Limited and various private equity funds, with a combined holding ratio that decreased by 1.97 percentage points compared to the previous quarter [1] Institutional Holdings - Among public funds, there was an increase in holdings from one fund, the Guotai CSI Animal Husbandry ETF, while two funds, including the Harvest Agricultural Industry Stock A and Guotai Location Advantage Mixed A, saw a decrease in holdings by 0.66% [2] - Four new public funds disclosed their holdings this period, including Chang'an Xinyue Consumer Mixed A and others, while 17 public funds were not disclosed this period, including notable funds like Penghua Quality Governance Mixed (LOF) A [2] - For social security funds, one fund, the Huatai-PineBridge Fund Management Co., Ltd. - Social Security Fund 423 Combination, was not disclosed this period [2] - Foreign investment sentiment showed an increase in holdings from one foreign fund, Hong Kong Central Clearing Limited, with a holding increase of 0.37% [2]

Group 1 - The core viewpoint of the article is that Reap Bio (SZ 300119) held its 26th meeting of the fifth board of directors on August 22, 2025, to review the agenda including the "2025 Semi-Annual Report" and its summary [1] - For the year 2024, the revenue composition of Reap Bio is as follows: 43.12% from veterinary biological products, 33.86% from veterinary drugs, 20.63% from pet supply chain, and 2.38% from other sources [1]

Summary of Reap Bio's Conference Call Company Overview - **Company**: Reap Bio - **Industry**: Animal Health and Veterinary Pharmaceuticals Key Financial Performance - **Revenue Growth**: 2025 H1 revenue reached 1.708 billion CNY, a year-on-year increase of 20.5% [3] - **Net Profit**: Net profit attributable to shareholders was 257 million CNY, up 58% year-on-year [3] - **Adjusted Net Profit**: Non-GAAP net profit was 188 million CNY, reflecting a 34% increase [3] - **Core Product Revenue**: Core product revenue was nearly 600 million CNY, a 33% increase [4] Segment Performance - **Poultry Vaccines**: Revenue from poultry vaccines grew by 24.7% to 610 million CNY [7] - **Livestock Vaccines**: Livestock vaccine revenue doubled, increasing by 110% [2] - **Pet Segment**: Pet segment revenue surged by 108%, primarily through the Zhongrui supply chain [2] Strategic Initiatives - **Innovation and R&D**: The company focused on technological innovation, obtaining multiple new veterinary drug registrations, including the world's first mRNA vaccine for food animals [2][6] - **Partnerships**: Strengthened collaborations with leading breeding groups and accelerated overseas expansion [6] - **Pet Medical Focus**: Aiming for at least 100 million CNY in revenue from the Reap brand and targeting 1 billion CNY in the pet supply chain [10] Government Procurement - **Government Sales**: Government procurement revenue increased by 182%, accounting for 5% of total sales [21] - **Key Products**: Significant growth in high pathogenic avian influenza and foot-and-mouth disease vaccines [21] Cost Management - **Raw Material Prices**: Fluctuations in raw material prices impacted cost control positively in Q2, with a decrease in prices aiding management [15] - **Dragonxiang Subsidiary**: The subsidiary played a crucial role in stabilizing production costs and improving profitability [15] Future Outlook - **Growth Projections**: The company expects to achieve over 800 million CNY in revenue and aims for a profit of around 20 million CNY for the year [27] - **Market Trends**: Anticipates continued growth in the pet and livestock segments, leveraging deep service models for large breeding groups [20][31] Challenges and Risks - **Market Competition**: The animal health market remains competitive, particularly in the poultry and livestock sectors [31] - **Price Pressures**: Ongoing price declines in downstream markets may pose challenges [20] Additional Insights - **Product Mix**: The shift towards higher-margin biological products has contributed to an increase in overall gross margin, which is expected to rise by at least one percentage point annually [30] - **Investment in Supply Chain**: The Zhongrui supply chain's performance has been strong, although profits have temporarily declined due to high initial investments [26] This summary encapsulates the key points from Reap Bio's conference call, highlighting financial performance, strategic initiatives, and future outlook while addressing potential challenges in the industry.

格隆汇8月25日丨瑞普生物(300119.SZ)公布半年度报告，报告期内，公司实现营业收入17.08亿元，较上 年同期增长20.53%；归属于母公司的净利润2.57亿元，较上年同期增长57.59%；扣除非经常性损益的归 属于母公司的净利润1.88亿元，较上年同期增长34.28%。 ...

证券日报网讯8月25日晚间，瑞普生物（300119）发布公告称，公司及控股子公司无逾期对外担保、无 涉及诉讼的对外担保及因担保被判决败诉而应承担损失的情形。 ...

Group 1 - The company, Reap Bio, announced a maximum guarantee of 15 million yuan for financing applications made by its subsidiaries to Industrial Bank Co., Ltd. Tianjin Branch, with a financing term of one year and a guarantee period of three years after the debt performance deadline [1] - As of the announcement date, the total guarantee amount provided by the company and its subsidiaries is approximately 247 million yuan, accounting for 5.54% of the company's latest audited net assets attributable to shareholders [1] - The cumulative external guarantee balance provided by the company and its subsidiaries is 90.16 million yuan, which also accounts for 2.02% of the company's latest audited net assets [1] Group 2 - For the year 2024, the revenue composition of Reap Bio is as follows: 43.12% from veterinary biological products, 33.86% from veterinary drugs, 20.63% from pet supply chain, and 2.38% from other sources [2] - The current market capitalization of Reap Bio is 10.9 billion yuan [2]

Core Viewpoint - Reap Bio (300119) reported a significant increase in revenue and net profit for the first half of 2025, driven by the growth in sales of veterinary biological products and improved gross margin contributions [1] Financial Performance - The company achieved an operating revenue of 1.708 billion yuan, representing a year-on-year growth of 20.53% [1] - The net profit attributable to shareholders reached 257 million yuan, marking a year-on-year increase of 57.59% [1] - Basic earnings per share were reported at 0.56 yuan [1] Business Segments - The sales proportion of veterinary biological products has been continuously increasing, contributing significantly to the overall performance growth [1] - The improvement in comprehensive gross margin has also played a crucial role in enhancing the company's financial results [1]

瑞普生物(300119.SZ)公告称，瑞普生物发布2025年半年度报告，公司实现营业收入17.08亿元，同比增 长20.53%；归属于上市公司股东的净利润为2.57亿元，同比增长57.59%。公司计划不派发现金红利，不 送红股，不以公积金转增股本。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...